Organic Cation Transporter-Mediated Renal Secretion of Ipratropium and Tiotropium in Rats and Humans

2010 ◽  
Vol 39 (1) ◽  
pp. 117-122 ◽  
Author(s):  
Takeo Nakanishi ◽  
Tsunemitsu Haruta ◽  
Yoshiyuki Shirasaka ◽  
Ikumi Tamai
2015 ◽  
Vol 43 (12) ◽  
pp. 1872-1881 ◽  
Author(s):  
Jia Yin ◽  
Haichuan Duan ◽  
Yoshiyuki Shirasaka ◽  
Bhagwat Prasad ◽  
Joanne Wang

2009 ◽  
Vol 37 (5) ◽  
pp. 1009-1016 ◽  
Author(s):  
Takashi Kano ◽  
Yukio Kato ◽  
Kimihiro Ito ◽  
Takuo Ogihara ◽  
Yoshiyuki Kubo ◽  
...  

1999 ◽  
Vol 276 (2) ◽  
pp. F323-F328 ◽  
Author(s):  
Rong Chen ◽  
Bih Fang Pan ◽  
Mamoru Sakurai ◽  
J. Arly Nelson

Renal secretion of organic cations and anions are pleiotropic, active processes in mammals. Some nucleosides such as deoxyadenosine (dAdo), 2-chlorodeoxyadenosine, and azidothymidine are secreted by human and rodent kidneys. Previous work (J. A. Nelson, J. F. Kuttesch, Jr., and B. H. Herbert. Biochemical Pharmacology 32: 2323–2327, 1983) indicated a role for the classic organic cation transporter (OCT) in the secretion of the dAdo analog, 2′-deoxytubercidin, by mouse kidney. Using [14C]tetraethylammonium bromide ([14C]TEA) as a substrate, we tested several renal cell lines for a nucleoside-sensitive OCT. American opossum kidney proximal tubule cells (OK) express a cimetidine-sensitive and metabolic-dependent ability to efflux TEA. Other classic OCT inhibitors and several nucleosides also inhibit TEA efflux by these cells in a manner reflecting structural specificity for the carrier. Inhibition of OCT by nucleosides is not a universal feature of OCTs, since TEA transport mediated by cloned rat kidney OCT2 in the Xenopus laevisoocyte system was not inhibited by the same nucleosides. In conclusion, OK cells appear to possess an OCT that may also transport some nucleosides by a novel carrier.


2021 ◽  
Vol 22 (12) ◽  
pp. 6439
Author(s):  
Blessy George ◽  
Xia Wen ◽  
Edgar A. Jaimes ◽  
Melanie S. Joy ◽  
Lauren M. Aleksunes

The organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1) mediate the renal secretion of drugs. Recent studies suggest that ondansetron, a 5-HT3 antagonist drug used to prevent nausea and vomiting, can inhibit OCT2- and MATE1-mediated transport. The purpose of this study was to test the ability of five 5-HT3 antagonist drugs to inhibit the OCT2 and MATE1 transporters. The transport of the OCT2/MATE1 probe substrate ASP+ was assessed using two models: (1) HEK293 kidney cells overexpressing human OCT2 or MATE1, and (2) MDCK cells transfected with human OCT2 and MATE1. In HEK293 cells, the inhibition of ASP+ uptake by OCT2 listed in order of potency was palonosetron (IC50: 2.6 μM) > ondansetron > granisetron > tropisetron > dolasetron (IC50: 85.4 μM) and the inhibition of ASP+ uptake by MATE1 in order of potency was ondansetron (IC50: 0.1 μM) > palonosetron = tropisetron > granisetron > dolasetron (IC50: 27.4 μM). Ondansetron (0.5–20 μM) inhibited the basolateral-to-apical transcellular transport of ASP+ up to 64%. Higher concentrations (10 and 20 μM) of palonosetron, tropisetron, and dolasetron similarly reduced the transcellular transport of ASP+. In double-transfected OCT2-MATE1 MDCK cells, ondansetron at concentrations of 0.5 and 2.5 μM caused significant intracellular accumulation of ASP+. Taken together, these data suggest that 5-HT3 antagonist drugs may inhibit the renal secretion of cationic drugs by interfering with OCT2 and/or MATE1 function.


2018 ◽  
Vol 56 (08) ◽  
pp. e250-e250
Author(s):  
S Guttmann ◽  
S Reinartz Groba ◽  
C Niemietz ◽  
V Sandfort ◽  
A Zibert ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document